RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Nykode Therapeutics A Stock

Nykode Therapeutics A Revenue 2024

Nykode Therapeutics A Revenue

7.17 M USD

Ticker

NYKD.OL

ISIN

NO0010714785

WKN

A2PZ5J

In 2024, Nykode Therapeutics A's sales reached 7.17 M USD, a -44.46% difference from the 12.9 M USD sales recorded in the previous year.

The Nykode Therapeutics A Revenue history

YEARREVENUE (undefined USD)GROSS MARGIN (%)
2029e728.111,24
2028e115.777,80
2027e115.777,80
2026e6.94130,19
2025e23.4638,49
2024e7.17126,01
202312.969,99
20227.17125,98
202133.96105,32
2020215100,33
2019--
20180.0170862,43
20170.0518776,90
20160.0237567,08

Nykode Therapeutics A Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Nykode Therapeutics A, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Nykode Therapeutics A from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Nykode Therapeutics A’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Nykode Therapeutics A. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Nykode Therapeutics A’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Nykode Therapeutics A’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Nykode Therapeutics A’s growth potential.

Nykode Therapeutics A Revenue, EBIT and net profit per share

DateNykode Therapeutics A RevenueNykode Therapeutics A EBITNykode Therapeutics A Net Income
2029e728.11 M undefined-689.49 M undefined-519.47 M undefined
2028e115.77 M undefined-681.41 M undefined-597.31 M undefined
2027e115.77 M undefined-497.07 M undefined-486 M undefined
2026e6.94 M undefined-79.59 M undefined-81.05 M undefined
2025e23.46 M undefined-61.48 M undefined-54.13 M undefined
2024e7.17 M undefined-59.67 M undefined-50.79 M undefined
202312.9 M undefined-56.36 M undefined-35.15 M undefined
20227.17 M undefined-50.66 M undefined-42.74 M undefined
202133.96 M undefined-7.73 M undefined-9.41 M undefined
2020215 M undefined181.34 M undefined149.77 M undefined
20190 undefined-13.19 M undefined-13.7 M undefined
201812,743 undefined-6.51 M undefined-6.31 M undefined
201748,091 undefined-3.36 M undefined-3.1 M undefined
201624,037 undefined-1.62 M undefined-1.6 M undefined

Nykode Therapeutics A stock margins

The Nykode Therapeutics A margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Nykode Therapeutics A. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Nykode Therapeutics A.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Nykode Therapeutics A's sales revenue. A higher gross margin percentage indicates that the Nykode Therapeutics A retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Nykode Therapeutics A's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Nykode Therapeutics A's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Nykode Therapeutics A's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Nykode Therapeutics A. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Nykode Therapeutics A's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Nykode Therapeutics A Margin History

Nykode Therapeutics A Gross marginNykode Therapeutics A Profit marginNykode Therapeutics A EBIT marginNykode Therapeutics A Profit margin
2029e125.98 %-94.7 %-71.35 %
2028e125.98 %-588.59 %-515.95 %
2027e125.98 %-429.36 %-419.8 %
2026e125.98 %-1,147.55 %-1,168.52 %
2025e125.98 %-262.07 %-230.71 %
2024e125.98 %-832.68 %-708.83 %
2023125.98 %-436.82 %-272.47 %
2022125.98 %-706.81 %-596.3 %
2021105.32 %-22.75 %-27.72 %
2020100.33 %84.34 %69.66 %
2019125.98 %0 %0 %
2018125.98 %-51,105.59 %-49,519.29 %
2017125.98 %-6,986.76 %-6,452.52 %
2016125.98 %-6,752.21 %-6,674.84 %

Nykode Therapeutics A Aktienanalyse

What does Nykode Therapeutics A do?

Vaccibody AS is a Norwegian biotechnology company that was founded in 2007. It is headquartered in Oslo and currently employs about 40 people. The company specializes in the development of individualized vaccines based on DNA-based technology. The idea for founding Vaccibody came about when the two founders, Agnete Fredriksen and Bjarne Bogen, were collaborating at the University of Oslo. They wanted to develop a method to personalize vaccines in order to increase their effectiveness and compatibility. Their discovery is based on the fact that T-cells play an important role in the immune system and can recognize specific target proteins produced by cancer cells or viruses. Vaccibody's business model is based on the development of individualized vaccines based on DNA-based technology. The company has several different areas, including cancer immunotherapy, infectious diseases, and personalized medicine. Vaccibody's vaccines can be used for various types of cancer, such as lung, breast, and prostate cancer. Vaccibody offers a range of products, including a vaccine against HPV (human papillomavirus) that is approved for women aged 9 to 45. This vaccine aims to reduce the risk of cervical cancer. Another product from Vaccibody is the prostate cancer vaccine VCD-001. This vaccine uses the antigen PSA (prostate-specific antigen), which occurs on the surface of prostate cancer cells, to stimulate the patient's immune system. Vaccibody is also working on the development of vaccines against COVID-19 and has already achieved initial positive results in preclinical studies. As part of its personalized medicine division, Vaccibody offers the DNA platform VACCIBODY®, which is used to manufacture individualized DNA vaccines. This technology allows the vaccine to be tailored specifically to the needs of each patient. Vaccibody has achieved many important milestones since its inception. In 2018, the company received a $12.5 million investment to further develop its cancer immunotherapy platform. In 2020, Vaccibody received an additional $43.5 million investment to advance the development of its COVID-19 vaccine. Overall, Vaccibody has the potential to change the way vaccines are developed and used. DNA-based technology offers many advantages over conventional vaccines, especially in personalized medicine. Vaccibody is working hard to further develop its technology and bring its products to market in order to improve the lives of people around the world. Nykode Therapeutics A ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding Nykode Therapeutics A's Sales Figures

The sales figures of Nykode Therapeutics A originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Nykode Therapeutics A’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Nykode Therapeutics A's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Nykode Therapeutics A’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Nykode Therapeutics A stock

How much revenue did Nykode Therapeutics A generate this year?

Nykode Therapeutics A has achieved a revenue of 7.17 M USD this year.

How much was the turnover of the company Nykode Therapeutics A compared to the previous year?

The revenue of Nykode Therapeutics A has increased by -44.46% decreased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of Nykode Therapeutics A?

The revenue of Nykode Therapeutics A is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of Nykode Therapeutics A measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of Nykode Therapeutics A so important for investors?

The revenue of Nykode Therapeutics A is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does Nykode Therapeutics A pay?

Over the past 12 months, Nykode Therapeutics A paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Nykode Therapeutics A is expected to pay a dividend of 0 USD.

What is the dividend yield of Nykode Therapeutics A?

The current dividend yield of Nykode Therapeutics A is .

When does Nykode Therapeutics A pay dividends?

Nykode Therapeutics A pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Nykode Therapeutics A?

Nykode Therapeutics A paid dividends every year for the past 0 years.

What is the dividend of Nykode Therapeutics A?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Nykode Therapeutics A located?

Nykode Therapeutics A is assigned to the 'Health' sector.

Wann musste ich die Aktien von Nykode Therapeutics A kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Nykode Therapeutics A from 12/18/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 12/18/2024.

When did Nykode Therapeutics A pay the last dividend?

The last dividend was paid out on 12/18/2024.

What was the dividend of Nykode Therapeutics A in the year 2023?

In the year 2023, Nykode Therapeutics A distributed 0 USD as dividends.

In which currency does Nykode Therapeutics A pay out the dividend?

The dividends of Nykode Therapeutics A are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Nykode Therapeutics A

Our stock analysis for Nykode Therapeutics A Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Nykode Therapeutics A Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.